R&D
Anticancer Drug/Personalized Anticancer Drug/Osteoarthritis/COPD/Neurodegenerative Diseases
-
01
Knee Osteoarthritis
-
Osteoarthritis is the most common form of arthritis. This degenerative condition occurs
when the cartilage in the joint and surrounding tissues wears down over time.
-
The Korean market of osteoarthritis treatments, including anti-inflammatory drug,
hyaluronic acid, knee replacement surgery, physical therapy, and oriental medicine therapy,
is projected to reach $1.5B. Knee osteoarthritis patients account for 45% of the disease’s total
burden. As of 2016, 2.7M people had knee osteoarthritis in Korea.
-
Knee osteoarthritis is a condition with high unmet medical needs and no cure
other than joint replacement surgery.
-
02
Therapeutics
Development
-
MDimune Inc. is in the process of developing therapeutics for knee osteoarthritis using
mesenchymal stem cell-derived vesicles (MSCDVs), which can be readily administered
into the knee joint cavity using a syringe.
-
The effects of MSCDVs treatment in pain relief and cartilage regeneration
were observed in the animal model of osteoarthritis.
-
Based on these promising results, an Investigational New Drug (IND) application
targeting knee osteoarthritis will be submitted in 2021.